Doctors thought for a long time that immunotherapy wouldn’t work fornon-small-cell lung cancer(NSCLC) and small-cell lung cancer (SCLC), the two most common types. But the past few years have seen several breakthroughs. By the time most people with lung cancer are diagnosed, the disease ...
non-small cell lung cancerPD-1PDL-1In this editorial, we highlight the exciting advances in immunotherapy for the treatment of non-small cell lung cancer, with nivolumab being the first immunotherapeutic agent to be approved by the US FDA for the treatment of squamous lung cancer and several ...
Immunotherapy for lung cancer: nonspecific immune stimulation Nonspecific immune stimulation has been investigated therapeutically in different cancers, including NSC lung cancer. One agent recently evaluated in NSC lung cancer is talactoferrin alfa, a recombinant form of human lactoferrin and an oral DC-...
Winter H, van den Engel NK, Rusan M, Schupp N, Poehlein CH, Hu HM, et al. Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis. 2011;3(2):105–14. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cel...
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated wit
Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer Lung cancer is the leading cause of cancer deaths worldwide, mainly because it is usually in the advanced stage at the time of diagnosis. Although great progress has been made in the diagnosis and treatment of lu...
A global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemother
With the first immunomodulating agents having been approved for treatment of selected lung cancer patients, there are high expectations that treatment outcomes may be improved with the incorporation of immunotherapies into the various treatment cascades. 展开 关键词:...
Scientists continue to research immunotherapies for lung cancer, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapy. They’re also looking to see if combinations of these drugs will help. The following immunotherapy drugs have been approved for use in advanced non-small-cel...
For more than three decades, care for small-celllung cancer(SCLC) remained mostly the same. That’s changing now -- doctors have a new option called immunotherapy. This line of treatment uses your body’s own immune system to fight cancer. ...